Pharmaceutical

ArsenalBio secures $325m to develop cell therapy programmes

ArsenalBio has secured $325m in a Series C financing round to propel its programmable cell therapy programmes through clinical development.

Sep 6, 2024 - 04:00
ArsenalBio secures $325m to develop cell therapy programmes
ArsenalBio has secured $325m in a Series C financing round to propel its programmable cell therapy programmes through clinical development.
Read the original article

Tags:

Previous Article

UK bans xylazine and 21 other substances to fight drug abuse

Next Article

Lilly and EVA Pharma to expand baricitinib access in Africa

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The scientist studying how fugitive fetal cells may affect maternal health

The scientist studying how fugitive fetal cells may aff...

Nov 1, 2023

STAT+: Venture capital firm General Catalyst wants to buy a health system

STAT+: Venture capital firm General Catalyst wants to b...

Oct 8, 2023

Opinion: STAT+: The necessary roughness of 2023 has set up a very promising 2024 for biotech jobs

Opinion: STAT+: The necessary roughness of 2023 has set...

Jan 20, 2024